UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 119

Sortiert nach

Oral Selinexor–Dexamethasone for Triple-Class Refractory Multiple Myeloma

The New England journal of medicine, 2019-08, Vol.381 (8), p.727-738

2019

Volltextzugriff (PDF)

Leukaemic vasculitis with myelodysplastic syndrome

The Lancet (British edition), 2015-08, Vol.386 (9992), p.501-502

2015

Volltextzugriff (PDF)

Cost-Effectiveness of First-Line Versus Second-Line Use of Daratumumab in Older, Transplant-Ineligible Patients With Multiple Myeloma

Journal of clinical oncology, 2021-04, Vol.39 (10), p.1119-1128

2021

Volltextzugriff (PDF)

Effect of leucovorin administration on mucositis and skin reactions in patients with peripheral T-cell lymphoma or cutaneous T-cell lymphoma treated with pralatrexate

Leukemia & lymphoma, 2019-10, Vol.60 (12), p.2927-2930

2019

Volltextzugriff (PDF)

Clinical Activity of Pralatrexate in Patients With Cutaneous T-Cell Lymphoma Treated With Varying Doses of Pralatrexate

Clinical lymphoma, myeloma and leukemia, 2018-11, Vol.18 (11), p.e445-e447

2018

Volltextzugriff (PDF)

Stem-Cell Transplantation for Amyloidosis: Improving Outcomes but Not for the Faint of Heart

Journal of clinical oncology, 2015-11, Vol.33 (32), p.3689-3690

2015

Volltextzugriff (PDF)

Differential effects of PD-L1 versus PD-1 blockade on myeloid inflammation in human cancer

JCI insight, 2020-06, Vol.5 (12)

2020

Volltextzugriff (PDF)

Clinical and Serologic Responses After a Two-dose Series of High-dose Influenza Vaccine in Plasma Cell Disorders: A Prospective, Single-arm Trial

Clinical lymphoma, myeloma and leukemia, 2017-05, Vol.17 (5), p.296-304.e2

2017

Volltextzugriff (PDF)

Carfilzomib, lenalidomide, and dexamethasone (KRd) versus bortezomib, lenalidomide, and dexamethasone (VRd) for initial therapy of newly diagnosed multiple myeloma (NDMM): Results of ENDURANCE (E1A11) phase III trial

Journal of clinical oncology, 2020-06, Vol.38 (18_suppl), p.LBA3-LBA3

2020

Volltextzugriff (PDF)

Tandem high-dose influenza vaccination is associated with more durable serologic immunity in patients with plasma cell dyscrasias

Blood advances, 2021-03, Vol.5 (5), p.1535-1539

2021

Volltextzugriff (PDF)

Chronic lymphocytic leukemia: prognostic factors and impact on treatment

Discovery medicine, 2011-02, Vol.11 (57), p.115-123

2011

Volltextzugriff (PDF)

Whole-exome sequencing in evaluation of patients with venous thromboembolism

Blood advances, 2017-07, Vol.1 (16), p.1224-1237

2017

Volltextzugriff (PDF)

Clinical and serologic responses following a two dose series of high-dose influenza vaccine in plasma cell disorders: a prospective, single-arm trial

Clinical lymphoma, myeloma and leukemia, 2017-03, Vol.17 (5), p.296-304.e2

2017

Volltextzugriff (PDF)

Cost-Effectiveness of Once-Weekly Selinexor, Bortezomib, and Dexamethasone (SVd) Versus Twice-Weekly Bortezomib and Dexamethasone (Vd) in Relapsed or Refractory Multiple Myeloma

Blood, 2020-11, Vol.136 (Supplement 1), p.51-52

2020

Volltextzugriff (PDF)

Use of Denosumab after Zoledronic Acid in Patients with Multiple Myeloma: Real-World Experience from 2015 to 2019 at Yale Cancer Center

Blood, 2021-11, Vol.138 (Supplement 1), p.4756-4756

2021

Volltextzugriff (PDF)

Outcomes Among Primary Refractory Multiple Myeloma Patients in the Era of Monoclonal Antibodies: The Yale Experience

Blood, 2021-11, Vol.138 (Supplement 1), p.1635-1635

2021

Volltextzugriff (PDF)

Early alterations in stem-like/marrow-resident T cells and innate and myeloid cells in preneoplastic gammopathy

JCI insight, 2019-06, Vol.4 (11)

2019

Volltextzugriff (PDF)

Daratumumab in the Clinic, a Real-Word Experience at Yale Cancer Center

Blood, 2019-11, Vol.134 (Supplement_1), p.5569-5569

2019

Volltextzugriff (PDF)

Impact of leucovorin on mucositis and skin reactions in pts with peripheral t-cell lymphoma (PTCL) and cutaneous t-cell lymphoma (CTCL) treated with pralatrexate

Journal of clinical oncology, 2016-05, Vol.34 (15_suppl), p.7558-7558

2016

Volltextzugriff (PDF)

Enhanced Global Disease Assessment with Advanced Imaging and Targeted Myeloma Lesion Biopsy Highlights Spatial Heterogeneity and Detects Residual Disease in Multiple Myeloma

Blood, 2022-11, Vol.140 (Supplement 1), p.7308-7310

2022

Volltextzugriff (PDF)

A Phase II Study of Isatuximab (SAR650984) (NSC-795145) for Patients with Previously Treated AL Amyloidosis (SWOG S1702; NCT#03499808)

Blood, 2020-11, Vol.136 (Supplement 1), p.20-21

2020

Volltextzugriff (PDF)

Advanced Imaging and Targeted Myeloma Lesion Biopsies to Enhance Global Response Assessment and Evaluate Spatial Heterogeneity in Multiple Myeloma

Blood, 2020-11, Vol.136 (Supplement 1), p.20-22

2020

Volltextzugriff (PDF)

1 – 25 von 119

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(111)
Mit Volltextzugriff
(106)

Publikationsform

Artikel
(115)
Bücher
(4)

Sprache

Englisch
(118)
Japanisch
(10)

Erscheinungsjahr

n.n

Thema

Science & Technology
(78)
Life Sciences & Biomedicine
(75)
Humans
(66)
Female
(47)
Male
(47)
Middle Aged
(33)
Respiratory System
(30)
Aged
(29)
Chronic Obstructive Pulmonary Disease
(23)
Risk Factors
(18)
Epidemiology
(15)
General & Internal Medicine
(14)
Pulmonary Disease, Chronic Obstructive - Epidemiology
(14)
Copd
(13)
Child
(12)
Smoking
(12)
United States - Epidemiology
(11)
Aged, 80 And Over
(10)
Critical Care Medicine
(10)
Disease Progression
(10)

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Oral Selinexor–Dexamethasone for Triple-Class Refractory Multiple Myeloma

Leukaemic vasculitis with myelodysplastic syndrome

Carfilzomib or bortezomib in combination with lenalidomide and dexamethasone for patients with newly diagnosed multiple myeloma without intention for immediate autologous stem-cell transplantation (ENDURANCE): a multicentre, open-label, phase 3, randomised, controlled trial

Cost-Effectiveness of First-Line Versus Second-Line Use of Daratumumab in Older, Transplant-Ineligible Patients With Multiple Myeloma

Selective Inhibition of Nuclear Export With Oral Selinexor for Treatment of Relapsed or Refractory Multiple Myeloma

Effect of leucovorin administration on mucositis and skin reactions in patients with peripheral T-cell lymphoma or cutaneous T-cell lymphoma treated with pralatrexate

Integrated safety profile of selinexor in multiple myeloma: experience from 437 patients enrolled in clinical trials

Clinical Activity of Pralatrexate in Patients With Cutaneous T-Cell Lymphoma Treated With Varying Doses of Pralatrexate

Stem-Cell Transplantation for Amyloidosis: Improving Outcomes but Not for the Faint of Heart

Differential effects of PD-L1 versus PD-1 blockade on myeloid inflammation in human cancer

Clinical and Serologic Responses After a Two-dose Series of High-dose Influenza Vaccine in Plasma Cell Disorders: A Prospective, Single-arm Trial

Carfilzomib, lenalidomide, and dexamethasone (KRd) versus bortezomib, lenalidomide, and dexamethasone (VRd) for initial therapy of newly diagnosed multiple myeloma (NDMM): Results of ENDURANCE (E1A11) phase III trial

Tandem high-dose influenza vaccination is associated with more durable serologic immunity in patients with plasma cell dyscrasias

Chronic lymphocytic leukemia: prognostic factors and impact on treatment

Whole-exome sequencing in evaluation of patients with venous thromboembolism

Clinical and serologic responses following a two dose series of high-dose influenza vaccine in plasma cell disorders: a prospective, single-arm trial

Cost-Effectiveness of Once-Weekly Selinexor, Bortezomib, and Dexamethasone (SVd) Versus Twice-Weekly Bortezomib and Dexamethasone (Vd) in Relapsed or Refractory Multiple Myeloma

Use of Denosumab after Zoledronic Acid in Patients with Multiple Myeloma: Real-World Experience from 2015 to 2019 at Yale Cancer Center

Outcomes Among Primary Refractory Multiple Myeloma Patients in the Era of Monoclonal Antibodies: The Yale Experience

Early alterations in stem-like/marrow-resident T cells and innate and myeloid cells in preneoplastic gammopathy

Daratumumab in the Clinic, a Real-Word Experience at Yale Cancer Center

Impact of leucovorin on mucositis and skin reactions in pts with peripheral t-cell lymphoma (PTCL) and cutaneous t-cell lymphoma (CTCL) treated with pralatrexate

Enhanced Global Disease Assessment with Advanced Imaging and Targeted Myeloma Lesion Biopsy Highlights Spatial Heterogeneity and Detects Residual Disease in Multiple Myeloma

A Phase II Study of Isatuximab (SAR650984) (NSC-795145) for Patients with Previously Treated AL Amyloidosis (SWOG S1702; NCT#03499808)

Advanced Imaging and Targeted Myeloma Lesion Biopsies to Enhance Global Response Assessment and Evaluate Spatial Heterogeneity in Multiple Myeloma

Suchergebnisse filtern